BACKGROUND: Although several reports have shown that proton beam therapy (PBT) offers promise for patients with skull base cancer, little is known about the frequency of late toxicity in clinical practice when PBT is used for these patients. Here, we conducted a retrospective analysis to clarify the late toxicity profile of PBT in patients with malignancies of the nasal cavity, para-nasal sinuses, or involving the skull base. METHODS: Entry to this retrospective study was restricted to patients with (1) malignant tumors of the nasal cavity, para-nasal sinuses, or involving the skull base; (2) definitive or postoperative PBT (>50 GyE) from January 1999 through December 2008; and (3) more than 1 year of follow-up. Late toxicities were graded according to the common terminology criteria for adverse events v4.0 (CTCAE v4.0). RESULTS: From January 1999 through December 2008, 90 patients satisfied all criteria. Median observation period was 57.5 months (range, 12.4-162.7 months), median time to onset of grade 2 or greater late toxicity except cataract was 39.2 months (range, 2.7-99.8 months), and 3 patients had toxicities that occurred more than 5 years after PBT. Grade 3 late toxicities occurred in 17 patients (19%), with 19 events, and grade 4 late toxicities in 6 patients (7%), with 6 events (encephalomyelitis infection 2, optic nerve disorder 4). CONCLUSIONS: In conclusion, the late toxicity profile of PBT in patients with malignancy involving the nasal cavity, para-nasal sinuses, or skull base malignancy was partly clarified. Because late toxicity can still occur at 5 years after treatment, long-term follow-up is necessary.
BACKGROUND: Although several reports have shown that proton beam therapy (PBT) offers promise for patients with skull base cancer, little is known about the frequency of late toxicity in clinical practice when PBT is used for these patients. Here, we conducted a retrospective analysis to clarify the late toxicity profile of PBT in patients with malignancies of the nasal cavity, para-nasal sinuses, or involving the skull base. METHODS: Entry to this retrospective study was restricted to patients with (1) malignant tumors of the nasal cavity, para-nasal sinuses, or involving the skull base; (2) definitive or postoperative PBT (>50 GyE) from January 1999 through December 2008; and (3) more than 1 year of follow-up. Late toxicities were graded according to the common terminology criteria for adverse events v4.0 (CTCAE v4.0). RESULTS: From January 1999 through December 2008, 90 patients satisfied all criteria. Median observation period was 57.5 months (range, 12.4-162.7 months), median time to onset of grade 2 or greater late toxicity except cataract was 39.2 months (range, 2.7-99.8 months), and 3 patients had toxicities that occurred more than 5 years after PBT. Grade 3 late toxicities occurred in 17 patients (19%), with 19 events, and grade 4 late toxicities in 6 patients (7%), with 6 events (encephalomyelitis infection 2, optic nerve disorder 4). CONCLUSIONS: In conclusion, the late toxicity profile of PBT in patients with malignancy involving the nasal cavity, para-nasal sinuses, or skull base malignancy was partly clarified. Because late toxicity can still occur at 5 years after treatment, long-term follow-up is necessary.
Authors: Bradford S Hoppe; Lauren D Stegman; Michael J Zelefsky; Kenneth E Rosenzweig; Suzanne L Wolden; Snehal G Patel; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-08 Impact factor: 7.038
Authors: Piet Dirix; Sandra Nuyts; Yasmyne Geussens; Mark Jorissen; Vincent Vander Poorten; Eric Fossion; Robert Hermans; Walter Van den Bogaert Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-14 Impact factor: 7.038
Authors: An Snyers; Geert O R J Janssens; Marcel B Twickler; Ad R Hermus; Robert P Takes; Arnoud C Kappelle; Matthias A W Merkx; Piet Dirix; Johannes H A M Kaanders Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-27 Impact factor: 7.038
Authors: Bradford S Hoppe; Carl J Nelson; Daniel R Gomez; Lauren D Stegman; Abraham J Wu; Suzanne L Wolden; David G Pfister; Michael J Zelefsky; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Dong Soo Lee; Yeon Sil Kim; Jae Seok Cheon; Jin Ho Song; Seok Hyun Son; Ji Sun Jang; Young Nam Kang; Jing Hyoung Kang; So Lyoung Jung; Ie Ryung Yoo; Hong Seok Jang Journal: Radiat Oncol Date: 2012-06-12 Impact factor: 3.481
Authors: David G Pfister; Sharon Spencer; David M Brizel; Barbara Burtness; Paul M Busse; Jimmy J Caudell; Anthony J Cmelak; A Dimitrios Colevas; Frank Dunphy; David W Eisele; Robert L Foote; Jill Gilbert; Maura L Gillison; Robert I Haddad; Bruce H Haughey; Wesley L Hicks; Ying J Hitchcock; Antonio Jimeno; Merrill S Kies; William M Lydiatt; Ellie Maghami; Thomas McCaffrey; Loren K Mell; Bharat B Mittal; Harlan A Pinto; John A Ridge; Cristina P Rodriguez; Sandeep Samant; Jatin P Shah; Randal S Weber; Gregory T Wolf; Frank Worden; Sue S Yom; Nicole McMillian; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2015-07 Impact factor: 11.908
Authors: Ming Fan; Jung Julie Kang; Anna Lee; Dan Fan; Huili Wang; Sarin Kitpanit; Pamela Fox; Kevin Sine; Dennis Mah; Sean M McBride; Chiaojung Jillian Tsai; Nadeem Riaz; Lara A Dunn; Eric J Sherman; Loren Michel; Bhuvanesh Singh; Ian Ganly; Richard J Wong; Jay O Boyle; Marc A Cohen; Nancy Y Lee Journal: Cancer Date: 2020-02-25 Impact factor: 6.860